Interview met Sandra Amor
De [URL="https://www.yumpu.com/nl/document/fulls ... ndom-ms-56"][U]Britse professor Sandra Amor[/U][/URL] is al sinds 1999 in Nederland voor haar onderzoek. Ze zoekt naar de oplossing voor MS in het brein en is er van overtuigd dat virusinfecties in de jeugd een rol spelen bij de ontwikkeling van MS.
Virussen
-
neuron
Heel leuk artikel over de behandeling van MS in Zweden.
[URL="https://www.ncbi.nlm.nih.gov/pubmed/29068493"]Managing Epstein-Barr virus and other risk factors in MS-Future perspectives[/URL].
.
[URL="https://www.ncbi.nlm.nih.gov/pubmed/29068493"]Managing Epstein-Barr virus and other risk factors in MS-Future perspectives[/URL].
.
-
neuron
Herkenning van het Epstein-Barr virus in multiple sclerose
Herkenning van het Epstein-Barr virus in multiple sclerose
Steeds vaker legt onderzoek een verband tussen MS en EBV.
Vandaag verschijnt het proefschrift van G.P. van Nierop (Gijs) in Nederland over MS en het EBV.
[B][URL="https://repub.eur.nl/pub/104289"]Recognition of Epstein-Barr Virus in Multiple Sclerosis[/URL][/B]
[URL="https://repub.eur.nl/pub/104289/Gijs-va ... te-PDF.pdf"]Het hele proefschrift kan je hier downloaden[/URL]
.
Steeds vaker legt onderzoek een verband tussen MS en EBV.
Vandaag verschijnt het proefschrift van G.P. van Nierop (Gijs) in Nederland over MS en het EBV.
[B][URL="https://repub.eur.nl/pub/104289"]Recognition of Epstein-Barr Virus in Multiple Sclerosis[/URL][/B]
[URL="https://repub.eur.nl/pub/104289/Gijs-va ... te-PDF.pdf"]Het hele proefschrift kan je hier downloaden[/URL]
.
-
neuron
MS veroorzaakt door een virus???
MS veroorzaakt door een virus???
Uit dit onderzoek (CHANGE-MS) blijkt dat virussen een rol spelen bij MS.
[QUOTE]GeNeuro is developing a new approach to treating MS by seeking to block mechanisms suspected of causing inflammation and neurodegeneration, rather than interfering with the body's immune response. This approach is the result of 25 years of research into human endogenous retroviruses (HERVs), including 15 years within the Institut Mérieux group and INSERM, before GeNeuro was founded in 2006.
That research led to the discovery of a potentially causal factor of multiple sclerosis: the MSRV-Env protein, which is expressed by genes that are normally silent. The presence of MSRV-Env in patients' brains could cause the inflammation and neurodegeneration that characterise MS.
GeNeuro has therefore developed GNbAC1, a monoclonal antibody currently in phase IIb of clinical development, as a treatment for multiple sclerosis. GNbAC1 neutralises MSRV-Env rather than targeting the patient's immune system, and could be a treatment that is both safe and effective in slowing or stopping the disease's progress in all its forms.[/QUOTE]
Uit dit onderzoek (CHANGE-MS) blijkt dat virussen een rol spelen bij MS.
[QUOTE]GeNeuro is developing a new approach to treating MS by seeking to block mechanisms suspected of causing inflammation and neurodegeneration, rather than interfering with the body's immune response. This approach is the result of 25 years of research into human endogenous retroviruses (HERVs), including 15 years within the Institut Mérieux group and INSERM, before GeNeuro was founded in 2006.
That research led to the discovery of a potentially causal factor of multiple sclerosis: the MSRV-Env protein, which is expressed by genes that are normally silent. The presence of MSRV-Env in patients' brains could cause the inflammation and neurodegeneration that characterise MS.
GeNeuro has therefore developed GNbAC1, a monoclonal antibody currently in phase IIb of clinical development, as a treatment for multiple sclerosis. GNbAC1 neutralises MSRV-Env rather than targeting the patient's immune system, and could be a treatment that is both safe and effective in slowing or stopping the disease's progress in all its forms.[/QUOTE]
-
neuron
CHANGE-MS studie
CHANGE-MS studie
GNC-003: an international, double-blind, randomized, placebo-controlled phase IIb trial to assess the efficacy, safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis
[url]http://www.geneuro.com/data/news/GNC003 ... IS2017.pdf[/url]
.
GNC-003: an international, double-blind, randomized, placebo-controlled phase IIb trial to assess the efficacy, safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis
[url]http://www.geneuro.com/data/news/GNC003 ... IS2017.pdf[/url]
.